Our pipeline
leadXpro uses its unique technology platform to develop proprietary preclinical compounds with high efficacy and specificity.
Contact us today to discuss licensing opportunities.
Selective Antagonists of the A2B Adenosine Receptor
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor.